Nicaragua vs Oman: Death rate from cancer
Nicaragua
39.65 deaths per 100,000 people
in 2021
Oman
39.97 deaths per 100,000 people
in 2021
Nicaragua rank
179th
Oman rank
178th
Death rate from cancer over time
- Nicaragua
- Oman
How they compare
Oman currently reports 39.97 deaths per 100,000 people against 39.65 deaths per 100,000 people in Nicaragua, a difference of 0.32 deaths per 100,000 people.
The two have swapped places 2 times across 22 shared years of data; in 2000 it was Oman ahead.
Nicaragua ranks 179th and Oman ranks 178th of 194 countries.
Across the 3 decades both report, Nicaragua averaged higher in 1 and Oman in 2.
Head to head by decade
| Decade | Nicaragua | Oman | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 38.37 deaths per 100,000 people | 48.38 deaths per 100,000 people | 10.01 deaths per 100,000 people | Oman |
| 2010s | 41.79 deaths per 100,000 people | 49.24 deaths per 100,000 people | 7.45 deaths per 100,000 people | Oman |
| 2020s | 41.11 deaths per 100,000 people | 40.87 deaths per 100,000 people | 0.245 deaths per 100,000 people | Nicaragua |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher death rate from cancer, Nicaragua or Oman?
- Oman, at 39.97 deaths per 100,000 people against 39.65 deaths per 100,000 people in Nicaragua as of 2021.
- What is the difference in death rate from cancer between Nicaragua and Oman?
- 0.32 deaths per 100,000 people, with Oman ahead.
- How many years of comparable data are there for Nicaragua and Oman?
- 22 years are reported by both, from 2000 to 2021.
- How do Nicaragua and Oman rank globally for death rate from cancer?
- Nicaragua ranks 179th and Oman ranks 178th of 194 countries.
- Where does this data come from?
- World Health Organization (2024) – with major processing by Our World in Data, published as Death rate from cancer. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Estimated number of deaths from malignant neoplasms in both sexes, per 100,000 people.